A. Shanafelt

发表

Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells.

F. Behm, D. Campana, C. Pui, 2001, Blood.

J. Bazan, N. Kabra, M. Howard, 1995, Journal of immunology.

An immune cell-selective interleukin 4 agonist.

J. Greve, A. Shanafelt, C. Forte, 1998, Proceedings of the National Academy of Sciences of the United States of America.

High affinity ligand binding is not essential for granulocyte-macrophage colony-stimulating factor receptor activation.

R. Kastelein, A. Shanafelt, Armen B. ShanafeltS, 1992, The Journal of biological chemistry.

Enhancing exposure of protein therapeutics.

J. M. Beals, J. Beals, A. Shanafelt, 2006, Drug discovery today. Technologies.

In vitro and in vivo systems to assess role of C-X-C chemokines in regulation of angiogenesis.

R. Strieter, S. Kunkel, D. Arenberg, 1997, Methods in enzymology.

Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity.

D. Wasserman, M. Michael, E. Berglund, 2009, Endocrinology.

Anchoring a cationic ligand: the structure of the Fab fragment of the anti-morphine antibody 9B1 and its complex with morphine.

Edwin Pozharski, Dagmar Ringe, G. Petsko, 2004, Journal of molecular biology.

FGF‐21/FGF‐21 receptor interaction and activation is determined by βKlotho

J. D. Dunbar, J. Hale, T. Coşkun, 2008, Journal of cellular physiology.

FGF21: a novel prospect for the treatment of metabolic diseases.

A. Shanafelt, A. Kharitonenkov, 2009, Current opinion in investigational drugs.

Requirement of hydrophilic amino-terminal residues for granulocyte-macrophage colony-stimulating factor bioactivity and receptor binding.

R. Kastelein, N. Meropol, S. Altmann, 1992, The Journal of biological chemistry.

The role of CXC chemokines in the regulation of angiogenesis in non‐small cell lung cancer

R. Strieter, S. Kunkel, D. Arenberg, 1997, Journal of leukocyte biology.

Identification of critical amino acid residues in human and mouse granulocyte-macrophage colony-stimulating factor and their involvement in species specificity.

R. Kastelein, A. Shanafelt, K. E. Johnson, 1991, The Journal of biological chemistry.

The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer.

R. Strieter, S. Kunkel, D. Arenberg, 1999, Journal of leukocyte biology.

Cloning and overexpression of the colicin E1 immunity gene.

R. Kastelein, A. Shanafelt, C. Kayalar, 1987, Plasmid.

Research Corrigendum

Christopher A. Carter, S. Roczniak, J. Greve, 2000, Nature Biotechnology.

The amino‐terminal helix of GM‐CSF and IL‐5 governs high affinity binding to their receptors.

R. Kastelein, A. Miyajima, T. Kitamura, 1991, The EMBO journal.

Medicinally useful proteins – enhancing the probability of technical success in the clinic

A. Shanafelt, 2005, Expert opinion on biological therapy.

Antibodies to murine CD40 stimulate normal B lymphocytes but inhibit proliferation of B lymphoma cells.

C. Hannum, E. Clark, R. Torres, 1993, Cellular immunology.

Identification of critical regions in mouse granulocyte-macrophage colony-stimulating factor by scanning-deletion analysis.

R. Kastelein, A. Shanafelt, Robert A. Kastelein, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Preference for occupancy of axial positions by substituents bonded to the heterocyclic ring in penta-O-acetyl-(+)-catechin in the crystalline state

G. Chiari, W. Mattice, F. Fronczek, 1985 .

Conformational analysis and dipole moments of tetra- O -methyl-(+)-catechin and tetra- O -methyl_(-)-epicatechin

W. Mattice, A. Shanafelt, F. L. Tobiason, 1982 .

Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs

T. Mcclanahan, D. Birnbaum, R. Kastelein, 1994, Nature.

The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis (*)

Armen B. Shanafelt, Steven L. Kunkel, Peter J. Polverini, 1995, The Journal of Biological Chemistry.

FGF-21 as a novel metabolic regulator.

J. Gromada, G. Sandusky, F. Mehrbod, 2005, The Journal of clinical investigation.

A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo

Christopher A. Carter, S. Roczniak, J. Greve, 2000, Nature Biotechnology.

The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.

Yun-Fei Chen, G. Etgen, B. Hansen, 2007, Endocrinology.

Colicin channels and cellular immunity.

A. Shanafelt, C. Kayalar, K. Goldman, 1984, Current topics in cellular regulation.

Diversity in hapten recognition: structural study of an anti-cocaine antibody M82G2.

G. Petsko, D. Ringe, E. Pozharski, 2005, Journal of molecular biology.

GM-CSF receptor: interactions and activation.

R. Kastelein, A. Shanafelt, 1993, Oncogene.

Fibroblast Growth Factor-21 as a Therapeutic Agent for Metabolic Diseases

A. Shanafelt, A. Kharitonenkov, 2012, BioDrugs.

Therapeutic enhancement of IL-2 through molecular design.

R. Martell, D. Cassell, S. Choudhri, 2002, Current pharmaceutical design.

Generation of Highly Selective VPAC2 Receptor Agonists by High Throughput Mutagenesis of Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Peptide*

C. Pan, S. Roczniak, Stephanie L. Yung, 2003, The Journal of Biological Chemistry.

Engineering of recombinant antibody fragments to methamphetamine by anchored periplasmic expression.

George Georgiou, Irina Baburina, G. Georgiou, 2006, Journal of immunological methods.

Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity.

D. Wasserman, M. Michael, E. Berglund, 2009, Endocrinology.